Kymera Therapeutics at citigroup summit: oral immunology push gains pace

On Thursday, 10 September 2026, Kymera Therapeutics (KYMR) highlighted its focus on oral immunology during Citigroup’s Biopharma Back to School Summit 2026. The company's STAT6 and IRF5 programs were the main drivers of this strategy, as Kymera aims to capitalize on unmet needs in diseases currently dominated by injectable biologics.

The presentation emphasized Kymera's belief in the large unmet need in atopic dermatitis and other type 2 inflammation diseases, where many patients still rely on topical treatments or lack advanced therapies. Early STAT6 data from a 22-patient Phase I-B study over 28 days were encouraging, with no conjunctivitis cases observed – a significant improvement over the expected baseline rate of 4% to 5%.

IRF5, another key program, boasts both human genetics and biological validation, making it a rare opportunity in immunology and potentially applicable to diseases like lupus, rheumatoid arthritis, Sjögren’s syndrome, and inflammatory bowel disease.

Kymera aims to become an independent commercial company and seeks a steady pipeline of new targets to support this goal. The CEO, Nello Mainolfi, noted that the company has been developing a targeted protein degradation platform over the past 10 years and has advanced seven molecules into clinical development.

The company's strategy centers around two lead programs, STAT6 (KT-621) and IRF5 (KT-579), with a focus on immunology, which is described as one of the largest markets in medicine and still dominated by biologics. Kymera plans to identify one new target each year and is exploring combination therapy opportunities and possible partnerships for programs that don't fit its core immunology focus.